Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR2 S252W |
| Therapy | Selumetinib |
| Indication/Tumor Type | endometrial carcinoma |
| Response Type | decreased response |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 S252W | endometrial carcinoma | decreased response | Selumetinib | Preclinical - Cell culture | Actionable | In a preclinical study, endometrial carcinoma cells harboring FGFR2 S252W demonstrated decreased sensitivity to Koselugo (selumetinib) in culture (PMID: 26438159). | 26438159 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26438159) | ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor. | Full reference... |